Description of the recent advances on the regulation of phosphate metabolism, gene mutations, and new approaches to treatment in patients with hypophosphatemic rickets.
INTRODUCTION
In 1937, Albright [1] described a patient with rickets and severe hypophosphatemia who did not show clinical and biochemical improvement by the administration of high doses of vitamin D. The term vitamin D-resistant rickets was coined, and later the disease was defined as X-linked hypophosphatemic rickets (XLHR).
Over the past two decades, clinical and basic investigations of disorders of phosphate metabolism have led to discoveries that have significantly advanced our understanding of phosphate regulation, with the evidence that XLHR is not the only hereditary form of hypophosphatemic rickets. Indeed, these disorders may be caused by mutations of genes involved in the complex regulation of phosphate metabolism. The discovery that fibroblast growth factor 23 (FGF23), a member of FGF family, mediates the combined renal tubular defects in phosphate reabsorption and altered vitamin D metabolism has given a new light to understand its role in hypophosphatemic disorders [2,3 & 
Furthermore, it has been shown that a-Klotho, named after a Greek goddess who spins the thread of life, a protein bearing b-glucuronidase activity expressed in renal tubules, is an essential cofactor for FGF23 action [5
GENE MUTATIONS AND CLINICAL FINDINGS OF HYPOPHOSPHATEMIC RICKETS
XLHR is the commonest form of renal phosphate wasting accounting for approximately 80% of the familial cases; its estimated prevalence is approximately 1 : 21 000. The main clinical findings of XLHR patients are growth failure with disproportionate short stature, rickets, and lower limb deformities. XLHR patients also show some peculiar dentinal and periodontal abnormalities, such as enlarged pulp chambers with prominent horns extending to the dentinoenamel junction that represent the main predisposing causes to the occurrence of periapical abscesses and fistula [6 & ]. Muscle weakness is an adjunctive feature in XLHR patients; lower muscle quality and limb deformities may contribute to this functional deficit [7] . XLHR is caused by inactivating mutations in phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) that is associated with increased circulating FGF23 levels.
An autosomal dominant rare form of hypophosphatemic rickets (ADHR) has been described. Clinical and biochemical findings of ADHR patients are similar to those of XLHR patients but ADHR, unlike XLHR, shows variable and incomplete penetrance with variable symptomatology and biochemical findings depending on the age at presentation. In ADHR patients high circulating levels of FGF23 are due to decreased FGF23 degration caused by activating mutations that impair proteolytic inactivation of FGF23 [8, 9 & ]. Moreover, two rare forms of autosomal recessive hypophosphatemic rickets (ARHR1 and ARHR2) caused by inactivating mutations of dentin matrix acidic phosphoprotein 1 (DMP1) or ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) genes have been reported, respectively. Both ARHR1 and ARHR2 are associated with increased circulating FGF23 levels. The clinical presentation of these forms is, surprisingly, not found at birth, but affected individuals present signs of rickets/osteomalacia later during childhood and even in adulthood [9 & ,10,11 & ,12] . Therefore, increased circulating levels of FGF23 are a common feature of XLHR, ADHR, and ARHR1-2
]. XLHR is the most prevalent cause of FGF23-related hypophosphatemic rickets, so that molecular analysis of PHEX gene should be the first screening step in determining the cause of FGF23-related hypophosphatemic rickets [13, 14] . In patients with clinical and biochemical signs of hypophosphatemic rickets no mutation in solute carrier family 34 (sodium/phosphate cotransporter), member 3 (SLC34A3), or chloride channel 5 (CLCN5) gene has been identified [14] .
Another rare form of hypophosphatemic rickets is the hereditary hypophosphatemic rickets with hypercalciuria (HHRH). HHRH is not FGF23mediated and is caused by a primary defect in phosphate transport across the renal tubular cells due to a mutation in SLC34A3 which encodes the NaPi-2c renal phosphate cotransporter [11 & ,15 && ,16 && ,17]. A form of X-linked recessive hypophosphatemic rickets has been identified too. Indeed, this condition comprises a group of disorders characterized by proximal renal tubular reabsorptive failure, hypercalciuria, nephrocalcinosis, and renal insufficiency. These disorders have also been referred to as the Dent disease complex [11 & ,18,19 & ]. The description of a patient affected by a peculiar form of hypophosphatemic rickets associated with hypercalcemia and hyperparathyroidism due to parathyroid hyperplasia led to the identification of a de-novo balanced translocation between chromosomes 9 and 13: t(9,13)(q21.13;q13.1) with a breakpoint adjacent to the Klotho gene [20] , suggesting an important regulating role of Klotho on phosphate metabolism. The elevated FGF23 and parathyroid hormone (PTH) levels in the patient provided evidence of Klotho's effects on these pathways in vivo. In addition to affect bone via indirect phosphate wasting pathways, supraphysiological FGF23 (and soluble Klotho) could directly impact bone in diseases with sustained elevated FGF23 levels [21 & ]. Table 1 shows the actual and other definitions, phenotype Mendelian Inheritance in Man number, location, and gene/locus of the various forms of hypophosphatemic rickets due to genetic mutation/translocation. [15 && ]. Serum alkaline phosphatase activity is usually elevated in children, but it may be normal in adults [11 & ]. In Table 2 the main biochemical features of the various forms of hypophosphatemic rickets due to gene mutation/translocation are summarized.
BIOCHEMISTRY OF HYPOPHOSPHATEMIC RICKETS

ROLE OF aKLOTHO/FIBROBLAST GROWTH FACTOR 23 AND MEPE-ASARM MOTIF/ PEPTIDES IN THE PATHOGENESIS OF HYPOPHOSPHATEMIC RICKETS
PTH-vitamin D axis has provided the basis for our knowledge on bone and mineral homeostasis, but recent discovery of the FGF23 bone-kidney axis regulating vitamin D metabolism and renal phosphate handling have led to new insights into physiology and pathophysiology of mineral metabolism. PTH and FGF23, which is produced by osteocytes and osteoblasts, are the main hormones regulating renal phosphate handling. Both PTH and FGF23 cause a decrease in phosphate reabsorption by downregulating the sodium phosphate cotransporters in the proximal tubule, thus, inducing phosphaturia and hypophosphatemia. PTH stimulates 1a-hydroxylase activity increasing 1,25(OH) 2 D production, and induces expression and secretion of FGF23. An important function of FGF23 is to act as a counter-regulatory hormone for 1,25(OH) 2 D in a bone-kidney feedback loop; indeed, FGF23, by inhibiting the activity of renal 1a-hydroxylase and stimulating that of 24-hydroxylase, diminishes the production of 1,25(OH) 2 D and increases its catabolism, respectively. Moreover, FGF23 could inhibit PTH production by an increase in 1a-hydroxylase activity at the parathyroid cells
Recent studies have shown that FGF23 requires Klotho protein as a coreceptor for high affinity binding to cognate FGF receptors (FGFRs). Klotho expression has been detected in the distal convoluted tubules of the kidney, the parathyroid gland, and the epithelium of the choroid plexus in the brain. Kl-knockout mice exhibit increased renal expression of NaPi-2a and NaPi-2c protein with concomitant hyperphosphatemia and develop the same physical, biochemical, and morphological characteristics as FGF23-knockout mice. The identical phenotypes of these two separate knockout lines led to the identification of Klotho as an essential cofactor in FGF23 signaling pathways. In humans, a homozygous loss of function mutation in Klotho causes tumoral calcinosis, severe hyperphosphatemia and ectopic calcification despite high serum levels of FGF23 in the affected patients proposed that a knockdown of family with sequence similarity 20-member C (FAM20C, also known as dentin matrix protein 4), that is secreted by osteoblasts/osteocytes, could lead to a remarkable downregulation of DMP1, along with a significant upregulation of FGF23 in both human and mouse osteogenic cell lines. FAM20C deficient mice showed rickets/osteomalacia with a defect in growth plate maturation and hypophosphatemia with elevated FGF23 levels.
These results indicate that FAM20C may mediate phosphate homeostasis via FGF23, but it is unclear if FAM20C regulates FGF23 directly or via DMP1.
The endocrine effects of PTH and Klotho/FGF23 complex on phosphate metabolism and their pathogenetic role on hypophosphatemic rickets, including a possible regulatory role of MEPE-ASARM 
Hereditary hypophosphatemic rickets with hypercalciuria
Hypophosphatemic rickets and hyperparathyroidism motif/peptides and FAM20C, are schematized in Fig. 1 .
IRON DEFICIENCY AFFECTS AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS PHENOTYPE BY REGULATING FIBROBLAST GROWTH FACTOR 23 PRODUCTION
Studies in ADHR mice [32] and humans [33 && ] have suggested that iron deficiency may be a trigger for dysregulation of FGF23 so inducing active disease; therefore, the onset of the disease is the product of gene-environment interactions. Imel et al. [33 && ] showed that serum iron was negatively correlated to both C-terminal FGF23 and intact FGF23 in ADHR patients. Healthy controls also demonstrated a negative relationship of serum iron with C-terminal FGF23 but no relationship with intact FGF23, indicating increased expression but cleavage to maintain homeostasis. Regulation of phosphate homeostasis and pathogenetic role of FGF23 in inducing hypophosphatemic rickets. PTH and FGF23, by the complex a-Klotho/FGFR, reduce expression of NaPi-2a and NaPi-2c in the proximal renal tubules, thereby diminishing phosphate reabsorption and increasing urinary phosphate excretion. PTH also increases renal 1a-hydroxylase activity and suppresses 24-hydroxylase activity, thereby increasing 1,25(OH) 2 D production, thus, enhancing intestinal phosphate absorption. Moreover, PTH induces expression and secretion of FGF23, and vice versa, FGF23 reduces expression and secretion of PTH. FGF23, by the complex a-Klotho/FGFR, decreases renal 1a-hydroxylase activity and stimulates 24-hydroxylase activity, thereby reducing 1,25(OH) 2 D production that, in turn, reduces intestinal phosphate absorption contributing to hypophosphatemia. Furthermore, 1,25(OH) 2 D promotes FGF23 synthesis and secretion by osteocytes while suppressing PTH synthesis and secretion by the parathyroid glands. In normal condition, ASARM (acidic serine aspartate-rich MEPE associated motif/peptides) could be a mediator of PHEX, DMP1, and ENPP1 in reducing FGF23 expression. In hypophosphatemic rickets, mutations in PHEX, DMP1, and ENPP1genes result in hypophosphatemia through increased FGF23 expression and stability causing phosphate wasting. Free ASARM, independently of PHEX, DMP1, and ENPP1, could also reduce expression of NaPi-2a in the proximal renal tubules with decreased renal phosphate reabsorption. In normal condition, FAM20C (family with sequence similarity 20-member C) could regulate DMP1 expression with downregulation of FGF23. In hypophosphatemic rickets, a knockdown of FAM20C could lead to a remarkable downregulation of DMP1, along with a significant upregulation of FGF23. A direct effet of FAM20C on FGF23 should be demonstrated. NaPi-2a and NaPi-2c: renal phosphate cotransporters. NaPi-2b: intestinal phosphate cotransporter. PiT-2: solute carrier family 20 (sodium-phosphate cotransporter), members 2. ?: mechanims to be demonstrated in humans. Ã: proposed mechanisms.
A 1,25(OH) 2 D driven increase in FGF23 production with phosphate wasting has been reported in Gambian children with rickets-like bone deformities due to chronically low calcium supply [34] ; a strong relationship between FGF23 and hemoglobin levels was also found [35 & ]. These studies suggest that iron status may regulate FGF23 metabolic pathways, and that low iron status results in increased FGF23 mRNA in ADHR phenotype and in Gambian children with nonvitamin D deficiency rickets.
IS FIBROBLAST GROWTH FACTOR 23 A MARKER OF SEVERITY OF DISEASE OR EFFECTIVENESS OF TREATMENT?
Relatively high FGF23 levels despite hypophosphatemia may be a useful tool to establish the diagnosis in addition to family history, bone deformities, and biochemical findings [36] . However, circulating levels of FGF23 did not correlate with any index of clinical (sex, age at onset, bone deformities) and biochemical (phosphate and alkaline phosphatase levels, and renal tubular phosphate reabsorption) severity of XLHR, or with the changes of phosphate levels in response to oral administration of phosphate salts [36] .
It has been shown that treatment of XLHR patients with calcitriol and phosphate salts is associated with concurrent increases in circulating FGF23 concentrations, but the consequences of worsening FGF23 concentrations are not yet clear [37] .
ROLE OF FIBROBLAST GROWTH FACTOR 23 OVERPRODUCTION AND PHEX MUTATION ON PARATHYROID HORMONE PRODUCTION
Secondary or tertiary hyperparathyroidism are known complications related to treatment of XLHR patients. The pathogenesis is multifactorial including phosphate mediated postprandial reduction in calcium levels, phosphate and FGF23 mediated reduction in 1,25(OH) 2 D production, and possible direct stimulating action of phosphate at the parathyroid cell. The role of FGF23 in inducing secondary or tertiary hyperparathyroidism is unknown and contrasts with the evidence that FGF23 directly decreases PTH secretion and increases 1a-hydroxylase activity at the parathyroid cells [38] .
The evidence of PHEX expression in parathyroid gland may suggest that hyperparathyroidism in XLHR patients is related to a loss of PHEX function in the parathyroid gland by either interfering with normal PTH mRNA cleavage or with the PTH degradation within or outside the parathyroid gland [38] .
Morey et al. [39] showed that XLHR patients with deleterious mutations of PHEX had lower tubular reabsorption of phosphate and serum 1,25(OH) 2 D levels; they seemed to be more at risk of developing hyperparathyroidism and nephrocalcinosis than patients with likely causative mutations. However, these results should be confirmed in a large number of XLHR patients taking into consideration the time of diagnosis and treatment received too.
CURRENT AND FUTURE TREATMENTS IN HYPOPHOSPHATEMIC RICKETS
Current treatment for patients with FGF23dependent hypophosphatemic rickets is based on the association of activated vitamin D metabolites (calcitriol or alfacalcidol) and oral inorganic phosphate salts. Treatment during growth partially corrects leg deformities, decreases the number of surgeries, and may improve adult height. Early initiation of treatment appears to optimize height outcomes [40 & ,41 & ]. Severity of disease and response/compliance with the treatment may significantly affect the phenotype.
Although an impaired growth hormone (GH)insulin like growth factor-I axis is not a primary cause of short stature in XLHR patients, the physiological antiphosphaturic effect of GH by the stimulation of phosphate retention may be an adjunctive tool, associated with the conventional treatment, to improve linear growth in poorly growing XLHR patients, without worsening of the degree of body disproportion [42 & ,43]. However, the results are not conclusive, as some patients do not have catch-up growth during GH treatment.
The evidence that increased FGF23 levels likely have a causative role in hypophosphatemic rickets suggests that the primary target of treatment should be the control of FGF23 overproduction. Liu et al. [44 & ] in XLHR patients showed that subcutaneous injection of salmon calcitonin caused a significant and sustained drop in circulating levels of FGF23, likely reducing its production by osteocytes, with an increase in serum phosphate levels. This suggests that calcitonin could be a therapeutic option for XLHR patients.
Studies in Hyp mice demonstrated that the inhibition of FGF23 overproduction by anti-FGF23 neutralizing antibodies, that may recognize either the receptor or Klotho-binding domain, improved phosphate levels, renal tubular phosphate reabsorption, bone mineralization, and muscle weakness, and enhanced longitudinal growth [45,46 && ]. These results indicate that inhibition of FGF23 activity is promising as a novel therapy for FGF23-dependent hypophosphatemia. However, further studies are needed to determine whether these findings in mice can be applied to humans. A summary of the main targets of treatment in patients with XLHR, ADHR, and ARHR 1-2 is depicted in Fig. 2 .
In contrast to patients with XLHR, ADHR, or ARHR1-2, treatment of HHRH patients consists of oral phosphate supplementation alone.
CONCLUSION
Considerable advances have been made in identifying genes responsible for a number of the inherited causes of hypophosphatemic rickets and to clarify the pathways of regulation of phosphate metabolism. The discovery that FGF23 overproduction is a primary cause of hypophosphatemic rickets may suggest a new approach for the treatment of these disorders. Although anti-FGF23 antibodies could be effective in the treatment of FGF23-dependent forms of hypophosphatemic rickets, further studies are needed to identify long-term efficacy and the potential side-effects. 
